Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
non-Hodgkin lymphoma
Pharma
Roche’s bispecific-ADC combo keeps lymphoma at bay
The positive Lunsumio-Polivy readout could give Roche another shot at second-line LBCL as its Columvi contends with a regulatory setback.
Angus Liu
Jun 23, 2025 10:27am
BMS angles Breyanzi for another blood cancer
Feb 10, 2025 9:50am
FDA approves Citius' Lymphir for cutaneous T-cell lymphoma
Aug 8, 2024 11:21am
AZ makes case for Calquence in another blood cancer type
Jun 17, 2024 11:25am
Inconsistent survival data dent Roche's Columvi win in 2L DLBCL
Jun 16, 2024 5:32pm
FDA spotlights timely cancer accelerated approval confirmation
Nov 15, 2023 8:20am
